Drug Profile

RC 1416

Alternative Names: Anti-IL-4R/IL-5 bispecific antibody; RC-1416; RC14/16

Latest Information Update: 29 Apr 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Regenecore Biotech
Class Antiasthmatics; Bispecific antibodies; Immunotherapies
Mechanism of Action Interleukin 4 receptor antagonists; Interleukin 5 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Phase II Asthma; Chronic obstructive pulmonary disease; Immunological disorders

06 Mar 2026 Phase-II clinical trials in Chronic obstructive pulmonary disease in China (SC) (NCT07402551)
11 Feb 2026 Nanjing RegeneCore Biotech plans a phase II trial for chronic obstructive pulmonary disease in China (SC, Injection) in March 2026 (NCT07402551)
11 Feb 2026 Regenecore Biotech plans a phase-II trial for Asthma (Treatment-experienced) in China (SC) (NCT07403487),

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com